NASDAQ:IQ

iQIYI, Inc. (NASDAQ:IQ) Navigates Competitive Streaming Market with Mixed Q1 2026 Financial Results

Font: Financial Modeling Prep  • May 18, 2026

Market Chart
  • Mixed Q1 Performance: iQIYI, Inc. (NASDAQ:IQ) reported better-than-expected earnings per share (EPS) and revenue, yet experienced an overall 13% decrease in total revenues year-over-year.
  • Shift to Net Loss: The company saw a significant reversal in profitability, moving from an operating income and net income in Q1 2025 to an operating loss and net loss in Q1 2026.
  • Financial Health Concerns: Key financial indicators, including a negative price-to-earnings (P/E) ratio of -36.94, a debt-to-equity ratio of 1.17, and a current ratio of 0.47, highlight ongoing financial challenges for the Chinese streaming giant.

iQIYI, Inc. (NASDAQ:IQ) is a major provider of online entertainment video services in China. The company operates in a competitive streaming market and focuses on premium content, artificial intelligence, and overseas growth. On May 18, 2026, iQIYI announced its financial results for the first quarter, which showed a mixed performance for the company.

The company reported an earnings per share (EPS) of -$0.03, which was better than the analyst consensus estimate of -$0.04. An EPS represents the company's profit allocated to each outstanding share of common stock. iQIYI also announced quarterly revenue of $903.19 million, slightly surpassing the estimated $903.01 million.

Despite beating estimates, total revenues of RMB 6.23 billion marked a 13% decrease from the same period last year, as highlighted by GlobeNewswire. Membership services revenue grew 2% to CNY 4.20 billion, but this was offset by a seasonal 8% decline in online advertising revenue, which came in at CNY 1.20 billion.

This revenue decline contributed to a significant shift in profitability. iQIYI reported an operating loss of RMB 228.40 million, a reversal from an operating income of RMB 341.90 million in the first quarter of 2025. This resulted in a net loss of RMB 294.60 million, compared to a net income of RMB 182.10 million a year prior.

The company's financial health shows some challenges. Its negative price-to-earnings (P/E) ratio of -36.94 indicates it was not profitable over the last year. Furthermore, a debt-to-equity ratio of 1.17 means the company holds more debt than equity. A current ratio of 0.47 also suggests its short-term debts are greater than its short-term assets.

Market Overview
VRAX
Virax Biolabs Group Limited
$0.24
53.09%
WGRX
Wellgistics Health, Inc.
$0.17
108.38%
AIM
AIM ImmunoTech Inc.
$0.41
61.26%
SBFM
Sunshine Biopharma, Inc.
$0.51
79.51%
SOXS
Direxion Daily Semiconductor Bear 3X ETF
$9.95
7.80%
TZA
Direxion Daily Small Cap Bear 3X ETF
$5.05
1.81%
PMI
Picard Medical, Inc.
$0.17
7.06%
GOVX
GeoVax Labs, Inc.
$2.21
79.67%
NXXT
NextNRG Inc.
$0.41
46.22%
CREG
Smart Powerr Corp.
$0.62
30.59%